One-hour meal tolerance test to assess withdrawal of insulin therapy in overweight patients with type 2 diabetes

Endocrine Practice

Volumn 7, Issue 4, 2001, Pages 256-261

  Kumar, D ^a   Luna Lollie, T ^a   Madha, S ^a  

^a LAC USC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; AUTOANTIBODY; C PEPTIDE; GLUCOSE; GLUTAMATE DECARBOXYLASE; INSULIN; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; SUCROSE; SULFONYLUREA;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC KETOACIDOSIS; DIET RESTRICTION; DOSE RESPONSE; DRUG WITHDRAWAL; ETHNIC GROUP; FEASIBILITY STUDY; FEEDING BEHAVIOR; FEMALE; FOLLOW UP; FOOD INTAKE; HOSPITALIZATION; HUMAN; HUMAN TISSUE; INSULIN RELEASE; INSULIN TREATMENT; MALE; MEDICAL DECISION MAKING; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; OUTPATIENT; POSTPRANDIAL STATE; SAFETY; TEST MEAL; VENOUS BLOOD;

EID: 0034894618     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.7.4.256     Document Type: Article

References (30)

1. When to use insulin in the maturity onset diabetic
2. Insulin use in NIDDM
3. Insulin therapy in type II diabetes: Who needs it, how much of it, and for how long?
4. Insulin treatment for the early 80s: Facts and questions about old and new insulins and their usage
5. Long-term normoglycemic remission in black newly diagnosed NIDDM subjects
6. The occurrence of diabetic ketoacidosis in non-insulin-dependent diabetes and newly diagnosed diabetic adults
7. Stimulated C-peptide and glucose levels as metabolic criteria to use insulin treatment in adult-onset type II diabetes
8. Stopping insulin treatment in middle-aged diabetic patients with high postglucagon plasma C-peptide: Effect on glycaemic control, serum lipids and lipoproteins
9. C-peptide profiling and type 2 diabetes treatment decisions
10. Classification of type 2 diabetes by clinical response to metformin-troglitazone combination and C-peptide criteria
11. Increasing prevalence of overweight among US adults: The National Health and Nutrition Examination Surveys, 1960 to 1991
12. Classification of newly diagnosed diabetic patients as insulin-requiring or non-insulin-requiring based on clinical and biochemical variables
13. Antibodies to glutamic acid decarboxylase reveal latent autoimmune diabetes mellitus in adults with a non-insulin-dependent onset of disease
14. Quantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes type
15. GAD antibodies in NIDDM: Ten-year follow-up from the diagnosis
16. Prevalence of glutamic acid decarboxylase auto-antibodies in Hispanic-American patients with diabetes mellitus
17. Distribution of autoantibodies to glutamic acid decarboxylase across the spectrum of diabetes mellitus seen in South Africa
18. Glucose toxicity
19. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: Genetic and clinical implications
20. The effect of insulin treatment on insulin secretion and insulin action in type II diabetes mellitus
21. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment
22. Restoration of sensitivity to sulfonylurea after strict glycaemic control with insulin in non-obese type 2 diabetic subjects
23. Insulin treatment reverses the insulin resistance of type II diabetes mellitus
24. Intensive conventional insulin therapy for type II diabetes: Metabolic effects during a 6-mo outpatient trial
25. One month's insulin treatment of type II diabetes: The early and medium-term effects following insulin withdrawal
26. Insulin therapy in obese, non-insulin-dependent diabetes induces improvements in insulin action and secretion that are maintained for two weeks after insulin withdrawal
27. Natural history of beta-cell dysfunction in NIDDM
28. Starting insulin therapy in patients with type 2 diabetes: Effectiveness, complications, and resource utilization
29. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)
30. Seminars in Medicine of the Beth Israel Hospital, Boston: Non-insulin-dependent diabetes mellitus - A genetically programmed failure of the beta cell to compensate for insulin resistance